Safe Orthopaedics announced on Tuesday, May 9, 2017, that sales for the first quarter 2017 rose 16% (excluding currency and acquisitions). Sales for the quarter were €763 thousand, which is up from €660 thousand reported in the first quarter of 2016. First quarter 2017 sales were adjusted for the discontinuation of activities in the United States from March 1, 2016.
Safe Orthpaedics Posts 16% First Quarter Sales Increase
1 min read Premium comments
Secondary
Safe Orthopaedics, which is based in Eragny-sur-Oise, France, specializes in sterile implants and single-use instruments for spinal surgery. The following table shows the sales details for first quarter 2017.
" data-large-file="https://i0.wp.com/ryortho.com/wp-content/uploads/2017/05/Safe-1Q17-Table.jpg?fit=730%2C157&ssl=1" src="https://i0.wp.com/ryortho.com/wp-content/uploads/2017/05/Safe-1Q17-Table.jpg?resize=730%2C157&ssl=1" alt="" width="730" height="157">Source: Safe Orthopaedics company documents
“Following a good performance in the fourth quarter of 2016, the pace of our expansion has continued to accelerate—both in France and in the rest of the world. That confirms the effectiveness of our new strategy, which has delivered clear benefits after just over six months”, said Pierre Dumouchel, Chief Executive Officer of Safe Orthopaedics.
He added, “2017 has gotten off to a very good start. Our recent sales hires in France and the launch of our operations in Germany make me firmly optimistic about the year as a whole. Thanks to the hard work by all our teams, Safe Orthopaedics is getting back on track.”
He added, “We are starting to reap the rewards of the strategy we have adopted since 2016 of turning the spotlight on our highly differentiated products, such as Oak and Cypress, and strengthening our sales and marketing teams in France and Germany. To accelerate this strategy and maintain our brisk pace of growth, we are currently looking at various financing options to safeguard as far as possible the interests of all our existing shareholders, who have supported us since our [initial public offer (IPO)].”
React:
Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.